Spots Global Cancer Trial Database for Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Precision Cell Immunotherapy Combined With TACE in Advanced Liver Cancer
Official Title: Clinical Study Using Precision Cell Immunotherapy Combination With Transcatheter Arterial Chemoembolization in Advanced Liver Cancer
Study ID: NCT02873442
Study Description
Brief Summary: To evaluate the safety and effectiveness of cell therapy using precision cells Combined With TACE in Advanced Liver Cancer. Eligibility: Individuals greater than or equal to 18 years of age and less than or equal to 65 years of age who have been diagnosed with Advanced Liver Cancer.
Detailed Description: A total of 40 patients may be enrolled over a period of 1-2 years.
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Ningbo No.5 Hospital (Ningbo Cancer Hospital), Ningbo, Zhejiang, China
Contact Details
Name: Huajun Jin
Affiliation: Shanghai Cell Therapy Research Institute
Role: STUDY_CHAIR
Name: Qijun Qian
Affiliation: Shanghai Cell Therapy Research Institute
Role: STUDY_CHAIR
Name: Jiangtao Wang
Affiliation: Ningbo No.5 Hospital (Ningbo Cancer Hospital)
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
